Login to Your Account


Get patients involved early in design of trials, Congress panel advised

By Randy Osborne
Staff Writer

Monday, July 14, 2014
The end of a two-part hearing on ways to speed clinical trials and include more diverse populations without introducing risk or mistakes included testimony by Alkermes plc CEO Richard Pops, who used his five minutes to propose a new framework for patients' help with trials that he said "would fundamentally transform the way we approach these [drug] development programs."

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription